Pharmacogenomics-guided personalized medicine in a clinical setting: real-world data

Systematic pharmacogenetic panel testing in clinical hyperpolypharmacy patients identified at least one DGI in 46% of the patients. Of these DGIs, 19% led to a recommendation for intervention. This study demonstrates that pharmacogenetic panel testing holds the potential to optimize pharmacotherapy in clinical hyperpolypharmacy patients.